Our previous study showed that solute carrier family 22 (organic cation transporter) member 18 (SLC22A18) downregulation via promoter methylation was associated with the development and progression of glioma, and the elevated expression of SLC22A18 was found to increase the sensitivity of glioma U251 cells to the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea. In this study, we investigated the possible upregulated expression of SLC22A18-induced enhancement of radiosensitivity of human glioma U251 cells in order to provide evidence in support of further clinical investigations. Stably overexpressing SLC22A18 human glioma U251 cells were generated to investigate the effect of SLC22A18 on the sensitivity of cells to irradiation in vitro using clonogenic survival assay. The apoptosis of U251 cells was examined with terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay. DNA damage and repair were measured using gH2AX foci. The effect of SLC22A18 on the in vivo tumor radiosensitivity was investigated in the orthotopic mice model. Upregulated expression of SLC22A18 enhanced the radiosensitivity of glioma U251 cells and also enhanced irradiation-induced apoptosis of U251 cells, but irradiation-induced apoptosis did not correlate with radiosensitizing effect of upregulated expression of SLC22A18. The repair of irradiation-induced double-strand-breaks was retarded in stably overexpressing SLC22A18 U251 cells. In the orthotopic mice model, the upregulated expression of SLC22A18 in U251 cells enhanced the effect of irradiation treatment and increased the survival time of mice. These results show that upregulated expression of SLC22A18 radiosensitizes human glioma U251 cells by suppressing DNA repair capacity.
INTRODUCTION
The success of use of radiotherapy as primary treatment modality of malignant tumors has been shown to correlate with the radiosensitivity of tumor cells, 1, 2 suggesting that tumors that cannot respond to irradiation may be resistant, the mechanisms for the radioresistance are not well known. 3 The process of oncogenic transformation often involves the accumulation of genetic changes that cause the resultant tumor more tolerant of irradiation than cells in the normal tissue of the patient. 4, 5 Thus, tumor cells resistance to irradiation could be because of abnormal functioning of genes, many of which have not been well defined.
Solute carrier family 22 (organic cation transporter) member 18 (SLC22A18), also known as IMPT1/BWR1A/TSSC5, is located within the human 11p15.5 cluster, and blast homology analysis suggests that SLC22A18 is a member of the family of polyspecific transporters and multidrug resistance genes. 6, 7 In recent years, SLC22A18 has been shown to be a tumor suppressor candidate, as well as a substrate for RING105. 8 Structural mutations in SLC22A18 are rare, with isolated reports of point mutations in a breast cancer cell line, Wilms' tumors and lung tumors, and a rhabdomyosarcoma cell line. 7 Exonic deletions in Wilms' tumors and loss of heterozygosity in hepatoblastomas have also been reported, 6, 9 indicating that SLC22A18 may have a very important role in tumorigenesis. We have previously found that SLC22A18 downregulation via promoter methylation was associated with the development and progression of glioma, and SLC22A18 represented a candidate biomarker for long-term survival in this disease. Stable overexpression of SLC22A18 inhibited growth and adherence, reduced tumor growth of glioma U251 cells in vitro and in vivo, suggesting that SLC22A18 is an important tumor suppressor in glioma. 10, 11 Recently, we have found that lack of SLC22A18 protein expression was a predictive tumor biomarker in GBM patients receiving temozolomide therapy. 12 We have also found that the elevated expression of SLC22A18 was found to increase the sensitivity of human glioma U251 cells to the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea. 13 In this study, we sought to investigate the effect of upregulated expression of SLC22A18 on the radiosensitization of human glioma U251 cells and its mechanism to provide a theoretical basis for clinical use. The data presented show that upregulated expression of SLC22A18 enhances the radiosensitivity of glioma U251 cells in vitro and in vivo by suppressing DNA repair capacity.
MATERIALS AND METHODS

Cell line and treatment
Transfection of tumor cells with pcDNA3.1-SLC22A18 As we have previously described, 10, 13 for stable transfection of the SLC22A18 gene, tumor cells (1 Â 10 6 ) were plated in six-well plates 24 h before transfection. Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used to mediate transfection using 5.0 mg of pcDNA3.1-SLC22A18 vector or 5.0 mg of empty pcDNA3.1 vector as a control according to the manufacturer's protocol. After 48 h transfection, the cells were selected in media supplemented with 150 mg ml À 1 G418. The medium was changed every 48 h Non-transfected cells died within 2 weeks. G418-resistant cells were selected and named as U251-SLC22A18. Cells with empty vector of pcDNA3.1 were named as U251-EV.
Western blotting analysis
At 48 h after transfection, tumor cells were washed in PBS and lysed in buffer using the standard methods. 14, 15 Lysates were cleared by centrifugation (14 000 r.p.m.) at 4 1C for 30 min. Protein samples (B40 mg) were separated by SDS-PAGE (15% gel), transferred to polyvinylidene difluoride membrane and non-specific-binding sites blocked by incubation in 5% non-fat milk for 60 min. Membranes were incubated at 4 1C overnight with anti-SLC22A18 antibody (1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-phospho-Akt antibody (Ser 473) (1:1000 dilution; Santa Cruz, CA, USA) or anti-phospho-Bad antibody (Ser136) (1:1000 dilution; Santa Cruz, CA, USA). Then the membrane was washed three times with tris-buffered saline with tween for 10 min and probed with the horseradish peroxidase-conjugated secondary antibody (1:2000 dilution; Dako, Glostrap, Denmark) for 30 min at room temperature, and after being washed three times, the membrane was developed using an enhanced chemiluminescence system (Pierce, Appleton, WI, USA). 16 Clonogenic survival assay Clonogenic assay were done as previously described. 17 Forty-eight hours after transfection, tumor cells were irradiated using a 137 Cs source (3.5 Gy min À 1 ) at room temperature. U251 cells were trypsinized and counted and known numbers were seeded onto 10-cm dishes. Colonies were stained with crystal violet 12 days after seeding, and the number of colonies contained 450 cells. The plating efficiency and survival of cells irradiated at doses of 0, 2 and 4 Gy were calculated and plating efficiency was calculated relative to that in untransfected controls and survival was calculated relative to that in unirradiated cells. Each assay was performed in triplicate.
Apoptosis assay
Apoptosis assay was performed using Apo-Direct terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling Assay kit (Millipore, Billerica, MA, USA). Cells were harvested and fixed in 4% paraformaldehyde for 60 min at 4 gH2AX assay U251 cells were grown overnight on coverslips in 35-mm dishes and transfected as described above. Dishes were irradiated with the 137 Cs source at a dose of 1.0 Gy. At 0, 0.25, 1, 2, 12 and 24 h after irradiation; cells were washed once with PBS and then fixed in 4% formaldehyde in PBS for 10 min at room temperature. Cells were permeabilized and blocked with blocking buffer (5% normal goat serum, 0.2% Triton X-100 in PBS) for 1 h and incubated with anti-gH2AX monoclonal antibody (1:100, Upstate Biotechnology, Lake Placid, NY, USA) overnight at 4 1 C. After washing with PBS twice, cells were incubated with fluorescein isothiocyanate-labeled rabbit anti-mouse antibody (1:100) for 1 h and washed twice with PBS. Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (1 mg ml À 1 ) in PBS for 30 min before cells were covered by anti-fade solution (Fisher, Pittsburgh, PA, USA) and mounted. Slides were visualized by a Leica DMRXA fluorescent microscope (Leica Microsystems Gmbh, Wetzlar, Germany). Images were captured by a Photometrics Sensys CCD camera (Roper Scientific, Tuscon, AZ, USA) and imported into IP Labs image analysis software package (Scanalytics, Fairfax, VA, USA). For each treatment condition, gH2AX foci were determined in 450 cells. Each assay was performed in triplicate.
The orthotopic U251 nude mice model Five-to six-week-old BALB/c athymic nude mice were used in this study. The animal experiments in this study were performed in compliance with the guidelines of the Medical School Institutes at Shanghai Jiao Tong University and Wuhan University. The glioma U251 cells were validated by previous studies in order to prepare them for transfer to the intracranial compartment, and these cells were trypsinized and re-suspended in PBS. A cell suspension including 1 Â 10 6 cells per 5 ml PBS was used for one implantation into the striatal region of the nude mouse brain. Nude mice were placed in a small-animal stereotactic frame (David Kopf Instruments, Tujunga, CA, USA) under the deep isoflurane anesthesia. A sagittal incision was made through the skin to expose the cranium, and a burr hole was drilled through the skull using a small dental drill 2.0 mm anterior and lateral (left) from the bregma. Cell suspension (5 ml) was injected at a depth of 3 mm from the brain surface. The needle was removed after 5 min, then the hole was sealed with bone wax and the wound was sutured immediately.
Animals were observed every day following tumor cells injection, and the healthy nude mice were randomized to radiation treatment group of 10 nude mice each 8 days after xenograft transplantation. Irradiation (2 Gy) each time was delivered to the entire head of the unanesthetized nude mice. The animals were immobilized in a plastic restraint through a single left lateral beam from a 137 Cs source. The remainder of the body was protected with a lead block. The irradiation schedule was used during the course of this study: 2 Gy Monday/Wednesday/Friday for 1 week (6 Gy in total) as established through preliminary studies. The body weight loss of animals was observed. The animals were killed by cervical dislocation when they presented signs of neurological disorders or when their body weight loss was 420% of their original weight, the time to this moment since surgery is considered as 'survival time'. Mice brains were embedded into optimal cutting temperature medium and quickly frozen in À 80 1 C after resection.
In vivo magnetic resonance imaging of tumor On day 7, 14 and 21 days post-tumor implantation glioma-bearing nude mice with or without irradiation were tested to examine the growth of the tumors. Glioma imaging in animal models was performed with a smallanimal coil on a High-Field GE Signa 3-Tesla clinical MR scanner (Signa; GE Healthcare, Waukesha, WI, USA), and images were gained by using a standard T1 protocol following gadolinium (Gd-DTPA; 100 ml per 20 g; Magnevist, Berlex Laboratories, Wayne, NJ, USA) intraperitoneal injection 10 min before examination. The scanning parameters were AxT1 FSE series-scan plane in enhanced scanning: phase field of view: 0.60; oblique; field of view: 5.0; spacing: 0.0 mm; slice thickness: 1.0 mm; freq directory: R/L; minimum repetition time: 60; and auto-repetition time: 600. Tumor sizes were measured and the tumor volumes (in mm 3 ) were calculated by the formula: volume ¼ (width) 2 Â length/2 using the Function Analysis software. 10, 19 The fluorescence immunostaining of tumor blocks from nude mice model
Glioma blocks from mice model were fixed with 4% paraformaldehyde and embedded in paraffin, and 10 slices were produced from each block. Followed by deparaffinization and hydration, the paraffin-embedded sections were processed for fluorescence immunostaining of Alex 594-labeled SLC22A18 and nuclei stained with 4 0 ,6-diamidino-2-phenylindole, and sections were examined on a Leica DMRXA fluorescent microscope (Wetzlar, Germany). Staining procedures and the microscopy settings were performed according to the protocol. Images were captured by a Photometrics Sensys CCD camera (Roper Scientific) and imported into IP Labs image analysis software package (Scanalytics).
Statistical analysis
Statistical analyses and graphs were performed using the Statistical Package for the Social Sciences (version 12.0, for Windows) (SPSS, Chicago, IL, USA). Quantitative values were expressed as mean ± s.d. Statistical differences between groups were examined using a Student's t-test or w 2 -test. P-values o0.05 were considered statistically significant. 18 
RESULTS
SLC22A18 expression U251 cells were tested for the basal levels of SLC22A18 by western blot analysis (Figure 1 ). U251 cells had a very small SLC22A18 protein level. After transfection with SLC22A18, western blot analysis also verified that SLC22A18 gene expression was enhanced in cells ( Figure 1 ). Levels of SLC22A18 protein expression in U251-SLC22A18 cells significantly increased, but U251-EV cells did not have a significant change in SLC22A18 protein levels.
The effects of upregulated expression of SLC22A18 on the radiosensitivity of U251 cells To evaluate the influences of upregulated expression of SLC22A18 on the radiosensitivity of human glioma U251 cells, clonogenic survival assays were done on the U251 cells. Upregulated expression of SLC22A18 caused a surviving fraction of B50% (Figure 2 ), which is in the proper range for determining clonogenic survival in combination with irradiation. Upregulated expression of SLC22A18 increased the radiosensitivity of cells with a doseenhancement factor at a surviving fraction of 0.10 of 1.46 for U251 cells as shown in Figure 2 .
The effects of upregulated expression of SLC22A18 on the irradiation-induced apoptosis Cells did undergo apoptosis after SLC22A18 transfection. U251-SLC22A18 cells were 7.2% TUNEL positive at 24 h compared with 4.4% of U251-EV cells and 1.7% of U251 cells. At 48 h after treatment, 14.8% of the U251-SLC22A18 cells were TUNEL positive, whereas only 4.8% of the U251-EV cells and 1.5% of the U251 cells were apoptotic (Figures 3a and c) . At 72 h, 9.5% of U251-SLC22A18 cells were TUNEL positive compared with 4.5% of the U251-EV cells and 1.4% of the U251 cells (Figure 3a) . Cells showed increased apoptosis if they had been transfected with SLC22A18 at 48 and 72 h after irradiation (Figure 3b ). U251-EV cells (18.6%) were TUNEL positive compared with 37.5% of U251-SLC22A18 cells at 48 h after irradiation (Figure 3c ). The PI3K-Akt pathway may regulate apoptosis through the phospho-Bcl-2-associated death promoter (pBAD) status, and BAD was one of the first targets of Akt to be identified with implications for cell survival. 20, 21 BAD is no longer able to bind to Bcl-2 and inhibit its anti-apoptotic activity when it is phosphorylated by phosphorylated serine/ threonine protein kinase (pAkt). In this study, we tested the phosphorylation status of Akt and Bad in U251-SLC22A18 cells, and found that both pAkt and pBAD were reduced (Figure 3d ). This response was associated with the apoptosis increase as shown in Figures 3a and b . These findings indicated that upregulated expression of SLC22A18 might lead to lower levels of pAkt-and pBAD-enhancing apoptosis. SLC22A18 retardation of DNA repair Irradiation causes DNA double-strand-breaks (DSBs) that are primarily repaired by the nonhomologous end-joining repair pathway. The phosphorylation of the histone H2AX at serine 139 is an initial step in the recognition of DSB. gH2AX foci form at a 1:1 ratio to DSBs at the site of the broken ends of DNA, making the number of foci a reliable sensitive indicator for DSB formation and their subsequent disappearance a measure of repair. 4, 5 The rate of DSB repair predicts the sensitivity of a cell to irradiation. 22, 23 In the present study, the number of phosphorylated gH2AX foci per cell at several times in 24 h following irradiation was counted to track the repair of DSBs created by irradiation. The repair of DSBs was retarded in U251-SLC22A18 cells. The cells had an average of 38.2 (U251), 37.2 (U251-EV) and 38.6 (U251-SLC22A18) foci per cell 15 min after a 1 Gy exposure. By 2 h after irradiation, the phosphorylated foci in U251 and U251-EV cells were mostly repaired, with 8.2 and 7.5 foci per cell, respectively, but there were still an average of 26.2 foci per cell in the U251-SLC22A18 cells. U251 cells had an average of 1.8 foci per cell, U251-EV cells 2.5 foci per cell and U251-SLC22A18 cells 8.2 foci per cell at 24 h (Figure 4 ). Upregulated expression of SLC22A18 improves the irradiation therapeutic efficacy on the nude mice bearing orthotopic xenografted glioma With the help of a small-animal stereotactic frame, 1 Â 10 6 glioma U251, U251-EV or U251-SLC22A18 cells were intracranially injected into the left caudate nucleus of 60 nude mice. Sixty nude mice bearing glioma were randomly divided into two groups at 8 days after injection according to the magnetic resonance imaging, including non-ionizing radiation and ionizing radiation. Each group includes U251, U251-EV and U251-SLC22A18 subgroup (10 nude mice in each subgroup). In 1 week the 6 Gy of total irradiation were conducted over three times. Each mouse survival time was recorded, and all survival times in each group were analyzed using Kaplan-Meier method. Our findings indicated that the irradiation treatment prolonged the survival time of nude mice in all group. With irradiation treatment, the nude mice in the U251-SLC22A18 group survived longest (53.2 days, average survival time) among the mice in three groups; the survival time of mice in the U251 group and the U251-EV group were 41.1 and 42.3 days, respectively, (Figure 5a ). Without irradiation treatment, the survival time of mice in the U251-SLC22A18 group was also longer than that in other groups, but the irradiation enhancement of survival time in the U251-SLC22A18 group was 39.6%, much higher than that in the U251 group and the U251-EV group, which Figure 1 . Western blot analysis for solute carrier family 22 (organic cation transporter) member 18 (SLC22A18) expression. U251 cells were transfected with either empty vector or SLC22A18 48 h before analysis. b-actin was used as loading control. Figure 2 . The Influences of upregulated expression of solute carrier family 22 (organic cation transporter) member 18 (SLC22A18) on the radiosensitivity of U251 cells. Cells were either transfected with either empty vector or SLC22A18 48 h before irradiation. After irradiation, cells were plated and they were allowed to form colonies.
was 20.9% and 20.5%, respectively. The differences between them were statistically significant (Po0.01).
According to the magnetic resonance image of gliomas on the 7th day after intracranial injection, glioma sizes in each group had some but not significant difference. After irradiation treatment, as shown in Figure 5b , the glioma size in the U251-SLC22A18 group on the 21st day did not show obvious growth compared with the glioma size of same mouse on the 7th day and the glioma sizes in the U251 group and the U251-EV group on the 21st day were significantly larger than the glioma size of same mouse on the 7th day. The average volumes of glioma in each group on the 21st day have been shown in Figure 5b ; although the glioma volumes are different in each group, the glioma sizes shrank more (63.5%) in the U251-SLC22A18 group than that in the U251 group (37.4%) and U251-EV group (41.7%). The fluorescence immunostaining of SLC22A18 protein level in tumor tissue on the 21st day was shown in Figure 5c .
DISCUSSION
We have previously found that SLC22A18 protein expression was significantly decreased in human gliomas compared with the adjacent normal brain tissues. SLC22A18 protein expression was significantly lower in gliomas that recurred within 6 months after surgery than gliomas that did not recur within 6 months. Multivariate Cox regression analysis indicated that SLC22A18 expression level was an independent survival prognostic factor for patients with glioma. SLC22A18 promoter methylation was Figure 3 . Analysis of irradiation-induced apoptosis. (a) Analysis of apoptosis induction after mock irradiation. U251 cells were either transfected with empty vector or solute carrier family 22 (organic cation transporter) member 18 (SLC22A18) 48 h before mock irradiation. Samples were taken at various times after the mock irradiation and analyzed for apoptosis, which was quantified on the basis of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) positivity. (b) Analysis of apoptosis induction after irradiation. U251 cells were either transfected with empty vector or SLC22A18 48 h before irradiation. Samples were taken at the indicated times and analyzed for apoptosis after the cells were irradiated at a dose of 5 Gy, which was quantified on the basis of TUNEL positivity. (c) Representative images of TUNEL assay in U251, U251-EV and U251-SLC22A18 cells 48 h after mock irradiation and irradiation. (d) Representative images of western blotting analysis of phosphorylated serine/threonine protein kinase (pAkt) and pBad expression in U251, U251-EV and U251-SLC22A18 cells. Cells were transfected with either empty vector or SLC22A18 48 h after mock irradiation before analysis. b-actin was used as loading control. *Po0.01 according to Student's t-test (U251 cells versus U251-SLC22A18 cells). **Po0.01 according to Student's t-test (irradiated U251 cells overexpressing SLC22A18 versus non-irradiated U251 cells overexpressing SLC22A18).
detected in 50% of the gliomas, but not in the adjacent normal tissues of any patient. SLC22A18 expression was significantly decreased in gliomas with SLC22A18 promoter methylation compared with gliomas without methylation. The SLC22A18 promoter was methylated in U251 cells, and treatment with the demethylating agent 5-aza-2-deoxycytidine increased SLC22A18 expression and reduced cell proliferation. Stable overexpression of SLC22A18 inhibited growth and adherence, induced apoptosis in vitro and reduced in vivo tumor growth of U251 cells. 10, 11, 24 We have also found that lack of SLC22A18 protein expression was a predictive tumor biomarker in GBM patients receiving temozolomide therapy, and elevated expression of SLC22A18 increased the sensitivity of U251 glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea. 12, 13 Recently, we have found that by increasing the expression of SLC22A18 hydroxyapatite nanoparticles could inhibit the growth of human glioma cells and enhance the radiosensitivity of tumor cells in vitro and in vivo. 2, 18 In this study, the results showed that upregulated expression of SLC22A18 induced a significant radiosensitization of human glioma U251 cells. We examined the phosphorylation status of Akt and Bad in U251-SLC22A18 cells, and found that both pAkt and pBAD were reduced. This response was associated with the apoptosis increase. These findings indicated that upregulated expression of SLC22A18 might lead to lower levels of pAkt-and pBAD-enhancing apoptosis. As we have shown here, upregulated expression of SLC22A18 in glioma U251 cells induces apoptosis directly and sensitizes the U251 cells to irradiation, presumably by retarding the repair of DSBs induced by irradiation. We implemented tests to investigate whether upregulated expression of SLC22A18 would restore irradiation-induced apoptosis in glioma U251 cells, although apoptosis generally does not occur in human glioma U251 cells irradiated in vitro. Not only did the U251-SLC22A18 cells showed a tendency for increased irradiationinduced apoptosis, but the U251-EV cells did as well. However, because empty vector did not result in radiosensitization as Figure 5 . Upregulated expression of solute carrier family 22 (organic cation transporter) member 18 (SLC22A18) improves the irradiation therapeutic efficacy on the nude mice bearing orthotopic xenografted glioma. (a) During reaching a moribund condition, the nude mice were killed, and all survival times in each group were analyzed using the Kaplan-Meier method. The irradiation enhancements of survival time in each group (n ¼ 10) were calculated by the formula: the survival time with irradiation divided by the survival time without radiation. The significance of irradiation enhancement difference between U251-SLC22A18 group and U251 group were analyzed by the w 2 method (*Po0.01). (b) The representative images from the U251, U251-EV or U251-SLC22A18 group were obtained by magnetic resonance imaging on the 7th and 21st day with ( þ IR, ionizing radiation), and the tumor volumes were calculated by the formula: volume ¼ (width) 2 Â length/2. *Po0.01 according to Student's t-test (U251 cells versus U251-SLC22A18 cells). (c) The representative SLC22A18 fluorescence immunostaining (red) in glioma sections from the U251, U251-EV or U251-SLC22A18 group and level of the SLC22A18 protein expression. The nuclei were visualized by 4 0 ,6-diamidino-2-phenylindole staining (blue). *Po0.01 according to Student's t-test (U251 cells versus U251-SLC22A18 cells).
indicated by clonogenic survival, we concluded that the ability of upregulated expression of SLC22A18 to enhance irradiationinduced apoptosis did not explain its radiosensitizing effects, and therefore sought other explanations. Irradiation kills tumor cells primarily by inducing DSBs, and these breaks are resealed by the complex processes of repair, but the extent and rate of DSB repair correlates with the radiosensitivity of tumor cell, that is, impeded DSB repair, as evidenced by the retention of gH2AX foci during the first 24 h after irradiation, correlates with enhanced radiosensitization. 25, 26 As shown here, in U251-SLC22A18 cells, but not in U251-EV cells, the repair of DNA DSBs induced by irradiation was retarded. All cells incurred an equivalent number of initial DSB, about 38 per cell, as measured by detecting and quantifying gH2AX foci 15 min after irradiation. The majority of DSBs induced by irradiation were repaired in U251 and U251-EV cells after 2 h, which then had 8.2 and 7.5 foci per cell, respectively. The U251-SLC22A18 cells still had an average of 26.2 foci per cell at the same time. This retardation in the rate of DSB repair in U251-SLC22A18 cells remained for 424 h, at which time there were four times more unrepaired breaks in the U251-SLC22A18 cells (8.2 foci per cell) than in U251 and U251-EV cells with 1.8 and 2.5 foci per cell, respectively.
In addition, our in vivo study have shown that the irradiation enhancement of survival time in the U251-SLC22A18 groups are highest (39.6%) compared with the U251-EV group (20.5%) and the U251 group (20.9%); the difference between the U251-SLC22A18 group and either U251 group or U251-EV group has statistical significance.
CONCLUSIONS
Collectively, our data demonstrate that upregulated expression of SLC22A18 enhanced the radiosensitivity of human glioma U251 cells and also enhanced irradiation-induced apoptosis of U251 cells. The repair of irradiation-induced DSBs was retarded in stably overexpressing SLC22A18 U251 cells. In the orthotopic mice model, the upregulated expression of SLC22A18 in U251 cells enhanced the effect of irradiation treatment and increased the survival time of mice. Our results show for the first time that upregulated expression of SLC22A18 radiosensitizes human glioma U251 cells by suppressing DNA repair capacity. ABBREVIATIONS SLC22A18, solute carrier family 22 (organic cation transporter) member 18; PBS, phosphate-buffered saline.
